Centogene GmbH, Germany, and Filgen Inc. are pleased to announce the start of a long-term exclusive partnership in Japan as of October 2015. The objective of this partnership is to provide better access to the highest quality genetic testing for rare hereditary disorders.
Beyond utilizing existing knowledge to the benefit of all patients, this collaboration involves the partner’s commitment to bring the best care possible to all Japanese patients. This ensures that every patient is treated with the best individual care, based on quality-driven and fast results.
Prof. Arndt Rolfs, CEO CENTOGENE states: “We are so thrilled to intensify with this collaboration education and awareness campaigns to support patients, physicians and healthcare systems in providing the best treatment”.